Serine/threonine-protein kinase N1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase N1 as ChEMBL target CHEMBL3384, mapped to UniProt Q16512. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Serine/threonine-protein kinase N1 matters
Serine/threonine-protein kinase N1 is reviewed as Serine/threonine-protein kinase N1 (UniProt Q16512); the current evidence base includes 11 approved drugs, 714 compounds, and 263 assays, with lead potency reaching pChEMBL 9.7.
Serine/threonine-protein kinase N1 Sequence length is 942 aa.
Review this target as Serine/threonine-protein kinase N1, mapped to UniProt Q16512. Sequence length is 942 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 11 approved drugs, 714 compounds, and 263 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Serine/threonine-protein kinase N1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q16512, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL3597011
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5687042
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL388978
|
8.9 | Kd | — |
|
|
No preferred name
CHEMBL5687026
|
8.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
TOFACITINIB CITRATE
CHEMBL2103743
|
2012 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |